Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The decision to close the NN2211-3619 trial was based on the very low recruitment rate as well as challenges relating to trial execution and study completion.

Conditions

Diabetes
Diabetes Mellitus, Type 1

Interventions

DRUG: liraglutide
DRUG: placebo

Sponsor

Novo Nordisk A/S